Clinical Trial Update: A Study of LY2216684 in Participants With Impaired Hepatic Function [Phase 1]

View source ↗

Summary

Phase 1 study of LY2216684 in participants with impaired hepatic function has completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• LY2216684

Snippet

Sponsor: Eli Lilly and Company | Conditions: Depressive Disorder, Major | Phase 1 | Status: COMPLETED | Results posted: 2018-10-22